Acquisitions - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2012 USD ($)	Dec. 31, 2012 Novozymes Biopharma Sweden Ab USD ($)	Dec. 31, 2011 Novozymes Biopharma Sweden Ab USD ($)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab USD ($)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab EUR (€)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab Up Front Payment USD ($)	Dec. 20, 2011 Novozymes Biopharma Sweden Ab Milestone Payment Arrangement EUR (€)	Dec. 31, 2012 Bio Flash Partners Limited Liability Company USD ($)	Jan. 29, 2010 Bio Flash Partners Limited Liability Company USD ($)	Jan. 29, 2010 Bio Flash Partners Limited Liability Company Milestone Payment Arrangement USD ($)
Business Acquisition [Line Items]
Business acquisition, consideration transferred		$ 28,056,000		$ 28,495,000				$ 2,640,000	$ 2,600,000
Business acquisition, contingent Payment						26,884,000	4,000,000			300,000
Business acquisition, probability-weighted fair value of contingent consideration				1,611,000	4,000,000
Fair Value of net assets acquired		29,236,000	28,922,000
Gain on bargain purchase		314,000	427,000
Business acquisition, Increase in contingent liability	618,000
Contingent consideration, current	1,322,000
Contingent consideration, non-current	1,033,000
Acquisition related costs incurred			1,700,000
Business acquisition, upfront payment				26,445,000				2,080,000	1,800,000
Estimated fair value of contingent consideration				$ 1,611,000				$ 560,000